263 related articles for article (PubMed ID: 20943749)
1. FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction.
Bravard A; Lefai E; Meugnier E; Pesenti S; Disse E; Vouillarmet J; Peretti N; Rabasa-Lhoret R; Laville M; Vidal H; Rieusset J
Diabetes; 2011 Jan; 60(1):258-68. PubMed ID: 20943749
[TBL] [Abstract][Full Text] [Related]
2. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
[TBL] [Abstract][Full Text] [Related]
3. Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.
Schrauwen P; Mensink M; Schaart G; Moonen-Kornips E; Sels JP; Blaak EE; Russell AP; Hesselink MK
J Clin Endocrinol Metab; 2006 Apr; 91(4):1520-5. PubMed ID: 16384852
[TBL] [Abstract][Full Text] [Related]
4. Hydrogen peroxide production is not primarily increased in human myotubes established from type 2 diabetic subjects.
Minet AD; Gaster M
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1486-90. PubMed ID: 21733990
[TBL] [Abstract][Full Text] [Related]
5. Regulation and function of FTO mRNA expression in human skeletal muscle and subcutaneous adipose tissue.
Grunnet LG; Nilsson E; Ling C; Hansen T; Pedersen O; Groop L; Vaag A; Poulsen P
Diabetes; 2009 Oct; 58(10):2402-8. PubMed ID: 19587359
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
[TBL] [Abstract][Full Text] [Related]
7. The expression of FTO in human adipose tissue is influenced by fat depot, adiposity, and insulin sensitivity.
Bravard A; Veilleux A; Disse E; Laville M; Vidal H; Tchernof A; Rieusset J
Obesity (Silver Spring); 2013 Jun; 21(6):1165-73. PubMed ID: 23913730
[TBL] [Abstract][Full Text] [Related]
8. Increased recovery rates of phosphocreatine and inorganic phosphate after isometric contraction in oxidative muscle fibers and elevated hepatic insulin resistance in homozygous carriers of the A-allele of FTO rs9939609.
Grunnet LG; Brøns C; Jacobsen S; Nilsson E; Astrup A; Hansen T; Pedersen O; Poulsen P; Quistorff B; Vaag A
J Clin Endocrinol Metab; 2009 Feb; 94(2):596-602. PubMed ID: 18984658
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
[TBL] [Abstract][Full Text] [Related]
10. A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus.
Pagel-Langenickel I; Schwartz DR; Arena RA; Minerbi DC; Johnson DT; Waclawiw MA; Cannon RO; Balaban RS; Tripodi DJ; Sack MN
Am J Physiol Heart Circ Physiol; 2007 Nov; 293(5):H2659-66. PubMed ID: 17890427
[TBL] [Abstract][Full Text] [Related]
11. Altered Skeletal Muscle Mitochondrial Proteome As the Basis of Disruption of Mitochondrial Function in Diabetic Mice.
Zabielski P; Lanza IR; Gopala S; Heppelmann CJ; Bergen HR; Dasari S; Nair KS
Diabetes; 2016 Mar; 65(3):561-73. PubMed ID: 26718503
[TBL] [Abstract][Full Text] [Related]
12. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Poulsen MK; Henriksen JE; Hother-Nielsen O; Beck-Nielsen H
Diabetes Care; 2003 Dec; 26(12):3273-9. PubMed ID: 14633813
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial reactive oxygen species generation in obese non-diabetic and type 2 diabetic participants.
Abdul-Ghani MA; Jani R; Chavez A; Molina-Carrion M; Tripathy D; Defronzo RA
Diabetologia; 2009 Apr; 52(4):574-82. PubMed ID: 19183935
[TBL] [Abstract][Full Text] [Related]
14. Effect of insulin deprivation on muscle mitochondrial ATP production and gene transcript levels in type 1 diabetic subjects.
Karakelides H; Asmann YW; Bigelow ML; Short KR; Dhatariya K; Coenen-Schimke J; Kahl J; Mukhopadhyay D; Nair KS
Diabetes; 2007 Nov; 56(11):2683-9. PubMed ID: 17660267
[TBL] [Abstract][Full Text] [Related]
15. Reduced lipid oxidation in skeletal muscle from type 2 diabetic subjects may be of genetic origin: evidence from cultured myotubes.
Gaster M; Rustan AC; Aas V; Beck-Nielsen H
Diabetes; 2004 Mar; 53(3):542-8. PubMed ID: 14988236
[TBL] [Abstract][Full Text] [Related]
16. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.
Bandyopadhyay GK; Yu JG; Ofrecio J; Olefsky JM
Diabetes; 2006 Aug; 55(8):2277-85. PubMed ID: 16873691
[TBL] [Abstract][Full Text] [Related]
17. Increased susceptibility to oxidative damage in post-diabetic human myotubes.
Costford SR; Crawford SA; Dent R; McPherson R; Harper ME
Diabetologia; 2009 Nov; 52(11):2405-15. PubMed ID: 19685293
[TBL] [Abstract][Full Text] [Related]
18. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes.
Ducluzeau PH; Perretti N; Laville M; Andreelli F; Vega N; Riou JP; Vidal H
Diabetes; 2001 May; 50(5):1134-42. PubMed ID: 11334418
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of xanthine oxidase reduces hyperglycemia-induced oxidative stress and improves mitochondrial alterations in skeletal muscle of diabetic mice.
Bravard A; Bonnard C; Durand A; Chauvin MA; Favier R; Vidal H; Rieusset J
Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E581-91. PubMed ID: 21224483
[TBL] [Abstract][Full Text] [Related]
20. v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats.
Maier VH; Melvin DR; Lister CA; Chapman H; Gould GW; Murphy GJ
Diabetes; 2000 Apr; 49(4):618-25. PubMed ID: 10871200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
